Research · Sep 3, 2026
[IT] Gartner Thesis 2026: Research Subscription Compounds Through GenAI Advisory Demand
Gartner Inc. FY2025 revenue ~$6.5-6.7B (+5-7%) with adj. EPS ~$11.80-12.20 reflecting continued IT research subscription growth + selected post-2023 Conferences segment recovery + selected Consulting growth + selected GenAI advisory demand under continued CEO Gene Hall. Leading global IT research + advisory + conferences firm focused on selected enterprise IT decision-makers + selected business leaders + selected supply chain professionals; founded 1979 by Gideon Gartner in Stamford Connecticut (originally as IT research firm; selected post-1979 ~46+ year heritage; IPO 1986; LBO 1990 by Saatchi & Saatchi; subsequent IPO 1993); headquartered in Stamford Connecticut; ~21,000+ employees globally with ~$6.5-6.7B revenue. 3 segments: Research 80% ($5.2B — IT enterprise leaders + Sales + Marketing + Finance + HR + Supply Chain research subscriptions; selected ~$6B+ contract value FY2025; selected ~6-8% YoY contract value growth; selected 100K+ enterprise client base; ~80%+ contract retention; selected ~2,500+ analysts proprietary research; ~25-30% segment operating margin) + Conferences 9% ($0.6B — selected ~30+ Symposium/IT events globally + selected post-2023 in-person conferences recovery + selected attendees ~75K+ annually; ~30%+ margin) + Consulting 11% ($0.7B — selected IT strategy + selected GenAI advisory + selected post-2023 GenAI consulting bookings; ~20%+ margin). CEO Gene Hall since October 2004 (succeeded Michael Fleisher CEO 1999-2004 retired; Hall ex-Imation CEO 2000-2004 + ex-3M Senior Vice President + selected ~30-year executive career). Key transactions: 2009 AMR Research $64M + 2010 Burton Group + April 2017 CEB $2.6B (transformational research expansion; selected best practice research + corporate executive board) + 2023-2024 GenAI advisory demand acceleration. Capital return: no dividend policy; buybacks $0.7-1.2B (selected aggressive ~1-2%/yr share count reduction); investment-grade Baa1/BBB+ credit rating; net debt $1.5-2B. FY2026 thesis: Research subscription compounding + Conferences recovery + GenAI advisory demand + capital return. Risks: enterprise IT subscription competitive intensity (Forrester + IDC + new GenAI research entrants), Conferences cyclicality, Consulting cyclicality, GenAI commoditization.